Back to User profile » Dr Qingjuan Ren
Papers published by Dr Qingjuan Ren:
Correlation of Body Mass Index with Clinicopathologic Parameters in Patients with Idiopathic Membranous Nephropathy [Corrigendum]
Chen X, Chen S, Li Z, Pan X, Jia Y, Hu Z, Niu K, Liu B, Ren Q
Diabetes, Metabolic Syndrome and Obesity 2025, 18:2707-2708
Published Date: 7 August 2025
Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study
Ren Q, Zhi L, Liu H
Drug Design, Development and Therapy 2025, 19:5645-5652
Published Date: 3 July 2025
Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum]
Niu S, Ren Q, Chen S, Pan X, Yue L, Chen X, Li Z, Zhen R
Diabetes, Metabolic Syndrome and Obesity 2023, 16:2833-2834
Published Date: 16 September 2023
Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice
Niu S, Ren Q, Chen S, Pan X, Yue L, Chen X, Li Z, Zhen R
Diabetes, Metabolic Syndrome and Obesity 2023, 16:2549-2560
Published Date: 24 August 2023
Metabolomics Provides Insights into Renoprotective Effects of Semaglutide in Obese Mice
Chen X, Chen S, Ren Q, Niu S, Pan X, Yue L, Li Z, Zhu R, Jia Z, Chen X, Zhen R, Ban J
Drug Design, Development and Therapy 2022, 16:3893-3913
Published Date: 9 November 2022
An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
Ren Q, Chen S, Chen X, Niu S, Yue L, Pan X, Li Z, Chen X
Drug Design, Development and Therapy 2022, 16:3723-3735
Published Date: 25 October 2022
Correlation of Body Mass Index with Clinicopathologic Parameters in Patients with Idiopathic Membranous Nephropathy
Chen X, Chen S, Li Z, Pan X, Jia Y, Hu Z, Niu K, Liu B, Ren Q
Diabetes, Metabolic Syndrome and Obesity 2022, 15:1897-1909
Published Date: 20 June 2022